Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Special Report Awards Gala Trending Oncology Supply Chain AI and Machine Learning Awards Outsourcing Awards Innovation Awards Pharma Marketing Awards Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Subscribe Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Special Report Awards Gala Trending Oncology Supply Chain AI and Machine Learning Awards Outsourcing Awards Innovation Awards Pharma Marketing Awards Resources Podcasts Fierce Events Industry Events Webinars Whitepapers Survey Events Subscribe Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Deadline Approaching: Apply for the Fierce AI Innovation Awards Pharma New Novartis MS pill racks up 10,000 U.S. users By Tracy Staton May 25, 2011 10:40am Pharma Novartis' new Gilenya multiple sclerosis pill is "doing very well" in the U.S., with more than 10,000 patients using the treatment, the Swiss drugmaker's head of development has said. Report Pharma
